Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Rochester, Minnesota

This page shows live ClinicalTrials.gov search results for Rochester, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9138
Shown on this page
12
Current sort
Recently updated
Location scope
Rochester, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Rochester, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 97–108 of 9,138 matching trials in Rochester, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Rochester

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Meningioma
Interventions
Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more
Conditions
Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions
[203Pb]Pb-PSV359, [212Pb]Pb-PSV359
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
625
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more
Conditions
Type2diabetes
Interventions
Caloric Restriction, Hyperglycemic clamp
Behavioral · Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
Ivosidenib 500mg, Placebo
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Conditions
Healthy
Interventions
Saline, Exendin-9,39, Liraglutide
Other · Biological
Lead sponsor
Adrian Vella
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Conditions
Acute Kidney Injury, Dialysis; Complications
Interventions
Continuous Renal Replacement Therapy (CRRT)
Device
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1026
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
Conditions
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
344
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 14 more